21:14 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

End of the road for Merck's anacetrapib

Merck & Co. Inc. (NYSE:MRK) said it will not seek regulatory approval of anacetrapib (MK-0859) to treat coronary heart disease (CHD). Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Although anacetrapib met the primary...
19:37 , Oct 12, 2017 |  BC Extra  |  Clinical News

End of the road for Merck's anacetrapib

Merck & Co. Inc. (NYSE:MRK) said it will not seek regulatory approval of anacetrapib (MK-0859) to treat coronary heart disease (CHD). Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Although anacetrapib met the primary...
21:57 , Jul 7, 2017 |  BioCentury  |  Product Development

One small CETP for Merck

Merck & Co. Inc. ’s massive cardiovascular outcomes trial for anacetrapib finally may have shown a CETP inhibitor provides a benefit. But the question remains whether the relative risk reduction is large enough for it...
22:33 , Jun 27, 2017 |  BC Extra  |  Clinical News

Merck's CETP inhibitor meets in CV outcomes study

Merck & Co. Inc. (NYSE:MRK) said cholesteryl ester transfer protein (CETP) inhibitor anacetrapib ( MK-0859 ) significantly reduced major coronary events in the Phase III REVEAL study, meeting its primary endpoint. Compared with placebo, anacetrapib...
08:00 , Jan 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cholesteryl ester transfer protein (CETP)

Cardiovascular disease INDICATION: Atherosclerosis In vitro and rodent studies identified a triphenylethanamine-based inhibitor of CETP that could help treat atherosclerosis. Chemical synthesis and in vitro testing of triphenylethanamine analogs identified a lead compound ( BMS-795311...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
01:56 , Nov 14, 2015 |  BC Extra  |  Clinical News

Merck continues anacetrapib CVOT

Merck & Co. Inc. (NYSE:MRK) intends to continue the 30,000-patient REVEAL cardiovascular outcomes trial (CVOT) of cholesteryl ester transfer protein ( CETP ) inhibitor anacetrapib ( MK-0859 ) to treat coronary heart disease (CHD). The...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

Evacetrapib: Development discontinued

Eli Lilly will discontinue development of evacetrapib to treat high-risk atherosclerotic cardiovascular disease after an IDMC recommended terminating the international Phase III ACCELERATE trial due to “insufficient efficacy.” Lilly said the IDMC based its recommendation...
01:05 , Oct 13, 2015 |  BC Extra  |  Top Story

Lilly discontinues Phase III CETP inhibitor

Eli Lilly and Co. (NYSE:LLY) fell $6.70 to $79.44 on Monday, losing more than $7 billion in market cap after it said it will discontinue development of cholesteryl ester transfer protein ( CETP ) inhibitor...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

Evacetrapib: Phase III ongoing

Eli Lilly said a DMC recommended continuation of the double-blind, placebo-controlled, international Phase III ACCELERATE trial evaluating 130 mg oral evacetrapib once daily for <=4 years in 12,095 patients based on data from an interim...